ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA

Hypertension Clinical Trial

Official title:

ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04899206
• Other study ID #: HUB-FC-2020-01
• Status: Active, not recruiting
• Start date: April 12, 2021
• Est. completion date: March 30, 2023

Study information

• Verified date: July 2022
• Source: Hospital Universitari de Bellvitge
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A retrospective cohort study will be performed by analyzing data obtained from the Catalan Southern Metropolitan data warehouse system, which collects data from both hospitalized and primary care patients from the Bellvitge University Hospital's area of influence. The investigators will begin by gathering information only on patients treated with antihypertensive drugs, which then will be stratified in two groups: 1) Angiotensin Agents group; 2) Other Antihypertensive Agents (Non-Angiotensin Agents) group. Afterwards, a separated analysis will be performed to assess the effects of ARBs and ACEIs separately on the prescription of antidepressant drugs.

Description:

Hypertension is a multifactorial disease and an important risk factor for cardiovascular and cerebrovascular diseases. Also, major depression is commonly found on these patients. Together, they represent a substantial burden for patients and their families, with an increased morbimortality and reduced life-quality. It also has a major social impact by increasing healthcare assistance demand and by affecting patients' daily-life productivity, therefore generating direct and indirect health-associated costs. The Renin-Angiotensin System is one of the known pathways that modulate systemic and central nervous system inflammation. Basic research studies have shown ARBs-related allosteric changes on receptors implicated on the pathophysiology of schizophrenia and depression, and also a pharmacological reversal of depression-like behavior in rats after the administration of losartan. Human research studies have also presented evidence that points towards an antidepressant effect of some antihypertensive drugs. A retrospective cohort study will be performed by analyzing data obtained from the Catalan Southern Metropolitan data warehouse system, which collects data from both hospitalized and primary care patients from the Bellvitge University Hospital's area of influence. The investigators will begin by gathering information only on patients treated with antihypertensive drugs, which then will be stratified in two groups: 1) Angiotensin Agents group; 2) Other Antihypertensive Agents (Non-Angiotensin Agents) group. Afterwards, a separated analysis will be performed to assess the effects of ARBs and ACEIs separately on the prescription of antidepressant drugs. Our primary objective is to estimate the prevalence, incidence, and clearance (incidence of antidepressant drugs withdrawal) of antidepressant drugs prescription in hypertensive patients under treatment with angiotensin agents (ARBs and/or ACEIs). Our secondary objectives are as follows: I. For ARBs: 1. To estimate the prevalence of antidepressant drugs prescription in hypertensive patients under treatment with ARBs. 2. To estimate the clearance of antidepressant drugs prescription in patients concomitantly treated with ARBs and antidepressant drugs. 3. To estimate the incidence of antidepressant drugs initiation in patients with hypertension treated with ARBs. II. For ACEIs: 1. To estimate the prevalence of antidepressant drugs prescription in hypertensive patients under treatment with ACEIs. 2. To estimate the clearance (incidence of antidepressant drugs withdrawal) of antidepressant drugs prescription in patients concomitantly treated with ACEIs and antidepressant drugs. 3. To estimate the incidence of antidepressant drugs initiation in patients with hypertension treated with ACEIs. III. For other antihypertensive drugs (i.e., non-angiotensin agents: CCBs, β-blockers, and diuretics): 1. To estimate the prevalence of antidepressant drugs prescription in hypertensive patients under treatment with other antihypertensive drugs (non-angiotensin agents). 2. To estimate the clearance (incidence of antidepressant drugs withdrawal) of antidepressant drugs prescription in patients concomitantly treated with other antihypertensive drugs and antidepressant drugs. 3. To estimate the incidence of antidepressant drugs initiation in patients with hypertension treated with other antihypertensive drugs. IV. To perform an exploratory comparative analysis among the different antihypertensive drugs sub-cohorts. The protocol (Final Version: February 18th, 2021) was approved by the local Institutional Review Board (Ethic-and-Clinical-Investigation- Committee, code HUB-FC-2020-01, date April 20th, 2021). The study findings will be submitted to peer-reviewed journals and presented at relevant national and international scientific meetings.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 120
• Est. completion date: March 30, 2023
• Est. primary completion date: December 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients that had an antihypertensive drug prescribed between January 1st, 2015 and December 31st, 2017, whose ATC codes can be obtained from the 'DATA WAREHOUSE' database
• Age = 18 years old
• Both genders
• Patients with information available on the 'DATA WAREHOUSE' database
• Patients with a clinical visit or prescription done afterwards the date when the information for the study was last collected (this way we ensure that the patient included on the study remained alive after the end of the observation period)

Exclusion Criteria:

• Lack of information about the beginning of treatment with an antihypertensive and/or with an antidepressant drug.

Related Conditions & MeSH terms

• ACE Inhibitors
• ARB
• Depression
• Hypertension

Intervention

Drug:
• With an Antidepressant Drug
Current users of an antidepressant drug.
• Without an Antidepressant Drug
Non-current users of an antidepressant drug.

Locations

Country	Name	City	State
Spain	Hospital Universitari de Bellvitge	L'Hospitalet De Llobregat	Catalonia

Sponsors (3)

Lead Sponsor	Collaborator
Sebastian Videla	Institut Català de la Salut, Institut d'Investigació Biomèdica de Bellvitge

Country where clinical trial is conducted

Spain, 

References & Publications (27)

Annerbrink K, Jönsson EG, Olsson M, Nilsson S, Sedvall GC, Anckarsäter H, Eriksson E. Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and monoamine metabolite concentrations in cerebrospinal fluid. Psychiatry Res. 2010 Sep 30;179(2):231-4. doi: 10.1016/j.psychres.2009.04.018. Epub 2010 May 16. — View Citation

Aso E, Lomoio S, López-González I, Joda L, Carmona M, Fernández-Yagüe N, Moreno J, Juvés S, Pujol A, Pamplona R, Portero-Otin M, Martín V, Díaz M, Ferrer I. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. Brain Pathol. 2012 Sep;22(5):636-53. doi: 10.1111/j.1750-3639.2011.00560.x. Epub 2012 Jan 13. — View Citation

Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78. doi: 10.5114/aoms.2015.56342. Epub 2015 Dec 11. — View Citation

Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-a mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014 Jan;62(1):145-57. doi: 10.1002/glia.22595. — View Citation

Brownstein DJ, Salagre E, Köhler C, Stubbs B, Vian J, Pereira C, Chavarria V, Karmakar C, Turner A, Quevedo J, Carvalho AF, Berk M, Fernandes BS. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018 Jan;52(1):24-38. doi: 10.1177/0004867417721654. Epub 2017 Jul 28. — View Citation

Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD. The mouse forced swim test. J Vis Exp. 2012 Jan 29;(59):e3638. doi: 10.3791/3638. — View Citation

Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012 Jan 28;(59):e3769. doi: 10.3791/3769. — View Citation

Cao YY, Xiang X, Song J, Tian YH, Wang MY, Wang XW, Li M, Huang Z, Wu Y, Wu T, Wu YQ, Hu YH. Distinct effects of antihypertensives on depression in the real-world setting: A retrospective cohort study. J Affect Disord. 2019 Dec 1;259:386-391. doi: 10.1016/j.jad.2019.08.075. Epub 2019 Aug 24. — View Citation

Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J. 1997;38(1):41-48. — View Citation

Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc. 2006;1(1):122-4. — View Citation

Farmer ME, Kittner SJ, Abbott RD, Wolz MM, Wolf PA, White LR. Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. J Clin Epidemiol. 1990;43(5):475-80. — View Citation

Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 13th edition, New York: McGraw-Hill Medical, 2018.

Grover MP, Ballouz S, Mohanasundaram KA, George RA, Sherman CD, Crowley TM, Wouters MA. Identification of novel therapeutics for complex diseases from genome-wide association data. BMC Med Genomics. 2014;7 Suppl 1:S8. doi: 10.1186/1755-8794-7-S1-S8. Epub 2014 May 8. — View Citation

Kessing LV, Rytgaard HC, Ekstrøm CT, Torp-Pedersen C, Berk M, Gerds TA. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study. Hypertension. 2020 Oct;76(4):1263-1279. doi: 10.1161/HYPERTENSIONAHA.120.15605. Epub 2020 Aug 24. — View Citation

Kessing LV, Rytgaard HC, Gerds TA, Berk M, Ekstrøm CT, Andersen PK. New drug candidates for depression - a nationwide population-based study. Acta Psychiatr Scand. 2019 Jan;139(1):68-77. doi: 10.1111/acps.12957. Epub 2018 Sep 4. — View Citation

Komada M, Takao K, Miyakawa T. Elevated plus maze for mice. J Vis Exp. 2008 Dec 22;(22). pii: 1088. doi: 10.3791/1088. — View Citation

Lenart L, Balogh DB, Lenart N, Barczi A, Hosszu A, Farkas T, Hodrea J, Szabo AJ, Szigeti K, Denes A, Fekete A. Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. Diabetologia. 2019 Aug;62(8):1501-1513. doi: 10.1007/s00125-019-4888-z. Epub 2019 May 3. — View Citation

Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Aug;94(31):e1317. doi: 10.1097/MD.0000000000001317. Review. Erratum in: Medicine (Baltimore). 2018 Jun;97(22):e11059. — View Citation

Lueptow LM. Novel Object Recognition Test for the Investigation of Learning and Memory in Mice. J Vis Exp. 2017 Aug 30;(126). doi: 10.3791/55718. — View Citation

Menéndez E, Delgado E, Fernández-Vega F, Prieto MA, Bordiú E, Calle A, Carmena R, Castaño L, Catalá M, Franch J, Gaztambide S, Girbés J, Goday A, Gomis R, López-Alba A, Martínez-Larrad MT, Mora-Peces I, Ortega E, Rojo-Martínez G, Serrano-Ríos M, Urrutia I, Valdés S, Vázquez JA, Vendrell J, Soriguer F. Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study. Rev Esp Cardiol (Engl Ed). 2016 Jun;69(6):572-8. doi: 10.1016/j.rec.2015.11.034. Epub 2016 Mar 12. English, Spanish. — View Citation

Miller RE, Shapiro AP, King HE, Ginchereau EH, Hosutt JA. Effect of antihypertensive treatment on the behavioral consequences of elevated blood pressure. Hypertension. 1984 Mar-Apr;6(2 Pt 1):202-8. — View Citation

Oliveira PA, Dalton JAR, López-Cano M, Ricarte A, Morató X, Matheus FC, Cunha AS, Müller CE, Takahashi RN, Fernández-Dueñas V, Giraldo J, Prediger RD, Ciruela F. Angiotensin II type 1/adenosine A (2A) receptor oligomers: a novel target for tardive dyskinesia. Sci Rep. 2017 May 12;7(1):1857. doi: 10.1038/s41598-017-02037-z. — View Citation

Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl). 1991;104(2):255-9. — View Citation

Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003 Feb 28;463(1-3):3-33. Review. — View Citation

Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population. J Postgrad Med. 2016 Oct-Dec;62(4):242-248. doi: 10.4103/0022-3859.188553. Review. — View Citation

Taura J, Valle-León M, Sahlholm K, Watanabe M, Van Craenenbroeck K, Fernández-Dueñas V, Ferré S, Ciruela F. Behavioral control by striatal adenosine A(2A) -dopamine D(2) receptor heteromers. Genes Brain Behav. 2018 Apr;17(4):e12432. doi: 10.1111/gbb.12432. Epub 2017 Nov 17. — View Citation

Williams LJ, Pasco JA, Kessing LV, Quirk SE, Fernandes BS, Berk M. Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders. Psychother Psychosom. 2016;85(4):250-2. doi: 10.1159/000444646. Epub 2016 May 27. — View Citation

* Note: There are 27 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patients treated with antihypertensive drugs	Number of patients under treatment with antihypertensive drugs	3 years
Primary	Patients treated with an antidepressant drug	Number of patients under treatment with antidepressant drug	3 years
Secondary	Patients diagnosed with Hypertension	Number of patients diagnosed with Hypertension	3 years
Secondary	Patients diagnosed with Depression	Number of patients diagnosed with Depression	3 years
Secondary	Patients treated with ARBs	Number of patients treated with ARBs	3 years
Secondary	Patients treated with ACEIs	Number of patients treated with ACEIs	3 years
Secondary	Patients treated with other antihypertensive drugs	Number of patients treated with other antihypertensive drugs (i.e., non-ARBs and non-ACEIs).	3 years
Secondary	Patients treated with Amitriptyline	Number of patients treated with Amitriptyline, since this is an antidepressant drug commonly used to treat neuropathic pain in our usual practice.	3 years
Secondary	Patients treated with Duloxetine	Number of patients treated with Duloxetine, since this is an antidepressant drug commonly used to treat neuropathic pain in our usual practice.	3 years